Denosumab in postmenopausal women with low bone mineral density.

By W. Rifkin. New England Journal of Medicine, 2006

1,159 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology, Orthopedics and Sports Medicine

View Paper: https://www.semanticscholar.org/paper/7a3c64e4cac9d031501e9bd9b1f7f804856c5757

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. S. Khosla
2. J. Smolen
3. J. Kanis
4. Chris Cooper
5. R. Baron
6. S. Ferrari
7. M. McClung
8. Qi Jiang

In Oncology

1. J. Kanis
2. S. Khosla
3. J. Smolen
4. Chris Cooper
5. K. Redlich
6. S. Ferrari
7. M. McClung
8. Qi Jiang

In Orthopedics and Sports Medicine

1. Chris Cooper
2. J. Kanis
3. S. Khosla
4. J. Smolen
5. K. Redlich
6. C. Roux
7. S. Ferrari
8. M. McClung

Citations in the corpus

• Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo‐Controlled FREEDOM Trial and Its Extension (2018, background): “Denosumab reduces bone resorption and improves bone mineral density (BMD).((1,2)) In FREEDOM, a 3-year random-”
• Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction (2006, background): “Recent progress in understanding the mechanism of bone loss in RA has provided promising new strategies, one of which is an anti-RANKL antibody directly suppressing RANKL-mediated osteoclastogenesis (51).”
• Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. (2010, methodology): “Antidenosumab antibody assessments were conducted using screening methods described previously.(28) RESULTS”
• Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. (2008, positive): “Denosumab administration in postmenopausal women with low BMD resulted in gains in BMD at the total hip, femoral neck, and distal radius at 12 and 24 months (230).”
• Denosumab and bisphosphonates: different mechanisms of action and effects. (2011, background): “Later studies investigated RANKL inhibition using denosumab, a fully human monoclonal antibody that targets RANKL [60].”
• Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards (2011, methodology): “The dose of 60 mg subcutaneously every 6 months was chosen as the licensed dose [80]”
• Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. (2011, methodology): “Assessments for antidenosumab antibodies were conducted using screening methods previously described.(33) Statistical analysis was conducted by Amgen in Thousand Oaks, CA.”
• Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems (2007, background): “In addition, the efficacy of a RANKL-specific antibody for postmenopausal osteoporosis and rheumatoid arthritis in clinical trials has been reporte”